Condition: Malignant Neoplasm · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| NEXT Oncology ( Site 0151) | San Antonio, Texas, United States | Recruiting |
| Rambam Health Care Campus ( Site 0051) | Haifa, Israel | Recruiting |
| Rabin Medical Center ( Site 0053) | Petah Tikva, Israel | Recruiting |
| National Cancer Center Hospital ( Site 0201) | Chūō, Tokyo, Japan | Recruiting |
| Cantonal Hospital St.Gallen ( Site 0101) | Sankt Gallen, Canton of St. Gallen, Switzerland | Recruiting |
| Ospedale Regionale Bellinzona e Valli ( Site 0104) | Bellinzona, Canton Ticino, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07600749